Streamline Bio is solving critical challenges in cell and gene therapy (CGT) manufacturing process to make CGT accessible to patients in need. In CGT, end-to-end automation is often hailed as the "holy grail", the solution to all the manufacturing problems and bottlenecks. However, CGT processes are inherently complex, multi-step, and notoriously variable; this makes it extremely difficult to develop an one-size-fits-all automation solution. That’s where we come in. Streamline Bio offers an AI-driven robotics platform that not only automates but is designed to be flexible, machine-agnostic, and fully digital-native.
Head of Automation
Cole Wu Seipel, Led a 7M dollars factory automation project.
Senior Mechanical Engineer
Melvin Liu, 6 years of experience in mechanical design.
Senior Software Engineer
Larry Huang, an experienced cloud-native software engineer on building SaaS platform.